Cargando…
Insulin Degludec, The New Generation Basal Insulin or Just another Basal Insulin?
The advances in recombinant DNA technology have led to an improvement in the properties of currently available long-acting insulin analogs. Insulin degludec, a new generation ultra-long-acting basal insulin, currently in phase 3 clinical trials, has a promising future in clinical use. When compared...
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Libertas Academica
2012
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3411522/ https://www.ncbi.nlm.nih.gov/pubmed/22879797 http://dx.doi.org/10.4137/CMED.S9494 |